A PROTAC probe named PD-Q2, composed of pomalidomide and the GPX4 inhibitor ML162, effectively induces degradation of GPX4 via the ubiquitin–proteasome system, leading to ROS accumulation and significant suppression of MM cell growth. This evidence concerns the gene GPX4 and Miyoshi myopathy.